A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate

Inclusion Criteria: * Has a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening. * Positive test for either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum at screening. * Has active RA defined as persistent disease activity with the following criteria: at least 6 swollen and 6 tender joints, and serum CRP ≥ 0.70 mg/dL at screening. * Has been treated with and tolerated methotrexate (MTX) treatment at dosages of 10 to 25 mg/week for a minimum of 6 months prior to screening and must be on a stable dose for a minimum of 8 weeks prior to screening * Must be post-menopausal or if pre-menopausal, must use an acceptable form of birth control * Has completed at least 5 days of daily pain diary in the 10 days prior to randomization. Exclusion Criteria: * Has inflammatory diseases other than RA, such as Lupus. * Is currently receiving treatment for RA other than methotrexate, NSAIDS, or oral corticosteroids such as prednisone, or pain medicines. * Has ever received any biologic agent for a rheumatic indication. * Has current signs or symptoms of liver insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled. * Has moderate or severe renal insufficiency * Has a recent (within 2 months) serious infection * Has had an opportunistic infection. * Has had cancer within the past 5 years (except certain skin or cervical conditions) * Has abused substances or alcohol within the past 2 years * Has active Hepatitis B or C infection * Has had active tuberculosis * Has had exposure to tuberculosis without preventative treatment